RU94046364A - Замещенные гетероциклы, способ их получения, фармокомпозиция, способ лечения - Google Patents
Замещенные гетероциклы, способ их получения, фармокомпозиция, способ леченияInfo
- Publication number
- RU94046364A RU94046364A RU94046364/04A RU94046364A RU94046364A RU 94046364 A RU94046364 A RU 94046364A RU 94046364/04 A RU94046364/04 A RU 94046364/04A RU 94046364 A RU94046364 A RU 94046364A RU 94046364 A RU94046364 A RU 94046364A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- pharmcomposition
- useful
- preparation
- substituted heterocycles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Замещенные гетероциклы являются антагонистами техикининового рецептора, полезными при лечении воспалительных заболеваний, боли или мигрени и астмы, и агентами, блокирующими кальциевые каналы, которые полезны при лечении сердечно-сосудистых состояний, таких как ангина, гипертония или ишемия.
Claims (1)
- Замещенные гетероциклы являются антагонистами техикининового рецептора, полезными при лечении воспалительных заболеваний, боли или мигрени и астмы, и агентами, блокирующими кальциевые каналы, которые полезны при лечении сердечно-сосудистых состояний, таких как ангина, гипертония или ишемия.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90597692A | 1992-06-29 | 1992-06-29 | |
US905,976 | 1992-06-29 | ||
US905976 | 1992-06-29 | ||
US97144892A | 1992-11-04 | 1992-11-04 | |
US971,448 | 1992-11-04 | ||
US6191493A | 1993-05-19 | 1993-05-19 | |
US061,914 | 1993-05-19 | ||
US061914 | 1993-05-19 | ||
PCT/US1993/006181 WO1994000440A1 (en) | 1992-06-29 | 1993-06-29 | Morpholine and thiomorpholine tachykinin receptor antagonists |
US971448 | 1997-11-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94046364A true RU94046364A (ru) | 1996-10-10 |
RU2140914C1 RU2140914C1 (ru) | 1999-11-10 |
Family
ID=27370159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94046364A RU2140914C1 (ru) | 1992-06-29 | 1993-06-29 | Замещенные гетероциклы или их фармацевтически приемлемая соль, фармацевтическая композиция для блокады рецепторов нейрокинина-1 у млекопитающих, способ для блокады рецепторов нейрокинина-1 у млекопитающих |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP0577394B1 (ru) |
JP (1) | JP2634372B2 (ru) |
KR (1) | KR100301212B1 (ru) |
CN (1) | CN1049431C (ru) |
AT (1) | ATE186532T1 (ru) |
AU (1) | AU4656193A (ru) |
BG (1) | BG62963B1 (ru) |
BR (1) | BR1100375A (ru) |
CA (1) | CA2099233A1 (ru) |
CY (1) | CY2200B1 (ru) |
CZ (1) | CZ288530B6 (ru) |
DE (1) | DE69326977T2 (ru) |
DK (1) | DK0577394T3 (ru) |
DZ (1) | DZ1700A1 (ru) |
ES (1) | ES2141133T3 (ru) |
FI (1) | FI111363B (ru) |
GR (1) | GR3031824T3 (ru) |
HK (1) | HK1009268A1 (ru) |
HR (1) | HRP931003B1 (ru) |
HU (1) | HU219713B (ru) |
IL (1) | IL106142A (ru) |
LV (1) | LV12568B (ru) |
MX (1) | MX9303888A (ru) |
MY (1) | MY108836A (ru) |
NO (1) | NO305698B1 (ru) |
NZ (1) | NZ254476A (ru) |
RO (1) | RO114448B1 (ru) |
RU (1) | RU2140914C1 (ru) |
SI (1) | SI9300346B (ru) |
SK (1) | SK281093B6 (ru) |
TW (1) | TW358808B (ru) |
WO (1) | WO1994000440A1 (ru) |
YU (1) | YU49036B (ru) |
ZA (1) | ZA934624B (ru) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5637699A (en) * | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
CZ288176B6 (en) * | 1993-12-29 | 2001-05-16 | Merck Sharp & Dohme | Substituted morpholine derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical preparations in which they are comprised |
US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
WO1995030674A1 (en) * | 1994-05-05 | 1995-11-16 | Merck Sharp & Dohme Limited | Morpholine derivatives and their use as antagonists of tachikinins |
PT777659E (pt) * | 1994-08-15 | 2001-09-28 | Merck Sharp & Dohme | Derivados de morfolina e sua utilizacao como agentes terapeuticos |
GB9417956D0 (en) * | 1994-09-02 | 1994-10-26 | Merck Sharp & Dohme | Therapeutic agents |
US5457107A (en) * | 1994-09-16 | 1995-10-10 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
FR2728165A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
GB9426103D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Therapeutic agents |
FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
DE19504627A1 (de) * | 1995-02-13 | 1996-08-14 | Bayer Ag | Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen |
GB9505492D0 (en) * | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9505491D0 (en) * | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9511031D0 (en) * | 1995-06-01 | 1995-07-26 | Merck Sharp & Dohme | Chemical process |
GB9513117D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9513118D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9513121D0 (en) * | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9523244D0 (en) * | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
PT785198E (pt) * | 1996-01-19 | 2000-11-30 | Lonza Ag | Processo para a producao de 3-quinuclidinol opticamente activo. |
GB9603136D0 (en) * | 1996-02-15 | 1996-04-17 | Merck Sharp & Dohme | Therapeutic agents |
GB9603137D0 (en) * | 1996-02-15 | 1996-04-17 | Merck Sharp & Dohme | Therapeutic agents |
UA56185C2 (ru) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкил- и аралкилиденгетероциклические лактамы и имиды, фармацевтическая композиция и способ лечения |
US6423708B1 (en) | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
JP2001502311A (ja) * | 1996-10-07 | 2001-02-20 | メルク シヤープ エンド ドーム リミテツド | 抗鬱及び/又は抗不安薬としてのcns浸透性nk―1受容体拮抗薬 |
US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
WO1998024445A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating schizophrenic disorders |
DE69731658T2 (de) * | 1996-12-02 | 2005-12-01 | Merck Sharp & Dohme Ltd., Hoddesdon | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen |
US6613765B1 (en) | 1996-12-02 | 2003-09-02 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating major depressive disorders |
AU733855B2 (en) * | 1996-12-02 | 2001-05-31 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating major depressive disorders |
US6100256A (en) * | 1996-12-02 | 2000-08-08 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptors antagonists for treating schizophrenic disorders |
EP0942733B1 (en) * | 1996-12-02 | 2005-04-27 | MERCK SHARP & DOHME LTD. | Use of nk-1 receptor antagonists for treating cognitive disorders |
JP2001504851A (ja) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 性的機能不全の治療のためのnk−1受容体拮抗薬の使用 |
US6114315A (en) * | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
WO1998024443A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating bipolar disorders |
US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
ES2231901T3 (es) * | 1996-12-02 | 2005-05-16 | MERCK SHARP & DOHME LTD. | Uso de antagonistas del receptor de nk-1 para tratar transtornos por el uso de sustancias. |
EP0941093B1 (en) * | 1996-12-02 | 2005-02-09 | MERCK SHARP & DOHME LTD. | Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
EP0942734A1 (en) * | 1996-12-02 | 1999-09-22 | MERCK SHARP & DOHME LTD. | Use of nk-1 receptor antagonists for treating severe anxiety disorders |
DE69730515T2 (de) * | 1996-12-02 | 2005-09-01 | Merck Sharp & Dohme Ltd., Hoddesdon | Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen |
RU2184538C2 (ru) * | 1997-01-09 | 2002-07-10 | Бифодан А/С | Применение дихлорбензилового спирта для получения лекарственного средства для местного лечения воспаления и лекарственное средство, содержащее дихлорбензиловый спирт |
CA2287487A1 (en) * | 1997-04-24 | 1998-10-29 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating eating disorders |
ZA985765B (en) * | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
CA2298777A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating mania |
GB9716457D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
AU737019B2 (en) * | 1997-08-04 | 2001-08-09 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating aggressive behaviour disorders |
US6087348A (en) * | 1997-12-01 | 2000-07-11 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating stress disorders |
US6271230B1 (en) | 1997-12-01 | 2001-08-07 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating cognitive disorders |
US6156749A (en) * | 1997-12-01 | 2000-12-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
GB9810920D0 (en) * | 1998-05-21 | 1998-07-22 | Merck Sharp & Dohme | Therapeutic use |
GB9816897D0 (en) * | 1998-08-04 | 1998-09-30 | Merck Sharp & Dohme | Therapeutic use |
GB9819888D0 (en) * | 1998-09-11 | 1998-11-04 | Merck Sharp & Dohme | Chemical synthesis |
US6218390B1 (en) * | 1998-12-17 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Morpholinone and morpholine derivatives and uses thereof |
ES2304984T3 (es) | 1999-11-03 | 2008-11-01 | Amr Technology, Inc. | Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina. |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
PT1103545E (pt) * | 1999-11-29 | 2004-03-31 | Hoffmann La Roche | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida |
RU2301808C2 (ru) | 2000-07-11 | 2007-06-27 | Эймр Текнолоджи, Инк. | 4-фенилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе |
GB0022988D0 (en) * | 2000-09-19 | 2000-11-01 | Merck Sharp & Dohme | Therapeutic agents |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
AU2003282665A1 (en) * | 2002-10-11 | 2004-05-04 | Cytokinetics, Inc. | Compounds, compositions, and methods |
WO2005090300A1 (en) | 2004-03-17 | 2005-09-29 | Pfizer Products Inc. | Novel benzyl(idene)-lactam derivatives |
GEP20094640B (en) | 2004-07-15 | 2009-03-10 | Bristol Myers Squibb Co | Aryl-and heteroaryl-substituted tetrahydro isoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
BRPI0613403A2 (pt) | 2005-07-15 | 2009-02-10 | Amr Technology Inc | tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina |
CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール |
EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
EP2254420A4 (en) | 2008-02-20 | 2012-02-15 | Targia Pharmaceuticals | CNS PHARMACEUTICALS AND METHOD FOR THEIR USE |
JP2011515343A (ja) | 2008-03-03 | 2011-05-19 | タイガー ファーマテック | チロシンキナーゼ阻害薬 |
WO2009124756A1 (en) * | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Use of aprepitant and derivatives thereof for the treatment of cancer |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
KR101830447B1 (ko) | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-([1,2,4]트리아졸로[1,5-α]피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
CN102638981B (zh) | 2009-10-14 | 2015-07-22 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子1受容体阻害剤 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
RU2660349C2 (ru) | 2012-11-28 | 2018-07-05 | Мерк Шарп И Доум Корп. | Композиции и способы для лечения злокачественной опухоли |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
CA3173697A1 (en) | 2020-04-03 | 2021-10-07 | Mike TROWER | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
EP4157270A1 (en) | 2020-06-02 | 2023-04-05 | NeRRe Therapeutics Limited | Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4476311A (en) * | 1980-03-12 | 1984-10-09 | The Purdue Frederick Company | Analgesic 4-carboxy-pyrrolidin-2-one compound |
JPS5739599A (en) * | 1980-08-20 | 1982-03-04 | Fuji Machine Mfg | Method and device for automatically mounting leadless electronic part on printed board or like |
FR2534915B1 (fr) * | 1982-10-26 | 1985-10-25 | Lafon Labor | Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation |
WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
US5459270A (en) * | 1991-08-20 | 1995-10-17 | Merck Sharp & Dohme Limited | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
-
1993
- 1993-06-25 IL IL106142A patent/IL106142A/xx not_active IP Right Cessation
- 1993-06-25 CA CA002099233A patent/CA2099233A1/en not_active Abandoned
- 1993-06-28 ZA ZA934624A patent/ZA934624B/xx unknown
- 1993-06-28 HR HR931003 patent/HRP931003B1/xx not_active IP Right Cessation
- 1993-06-28 MY MYPI93001250A patent/MY108836A/en unknown
- 1993-06-28 MX MX9303888A patent/MX9303888A/es unknown
- 1993-06-29 NZ NZ254476A patent/NZ254476A/en not_active IP Right Cessation
- 1993-06-29 SI SI9300346A patent/SI9300346B/sl unknown
- 1993-06-29 YU YU45293A patent/YU49036B/sh unknown
- 1993-06-29 CN CN93109517A patent/CN1049431C/zh not_active Expired - Lifetime
- 1993-06-29 HU HU9403804A patent/HU219713B/hu unknown
- 1993-06-29 RU RU94046364A patent/RU2140914C1/ru active
- 1993-06-29 RO RO94-02095A patent/RO114448B1/ro unknown
- 1993-06-29 AT AT93305086T patent/ATE186532T1/de active
- 1993-06-29 KR KR1019940704776A patent/KR100301212B1/ko not_active IP Right Cessation
- 1993-06-29 JP JP5212045A patent/JP2634372B2/ja not_active Expired - Lifetime
- 1993-06-29 CZ CZ19943330A patent/CZ288530B6/cs not_active IP Right Cessation
- 1993-06-29 EP EP93305086A patent/EP0577394B1/en not_active Expired - Lifetime
- 1993-06-29 DZ DZ930080A patent/DZ1700A1/fr active
- 1993-06-29 SK SK1600-94A patent/SK281093B6/sk not_active IP Right Cessation
- 1993-06-29 DK DK93305086T patent/DK0577394T3/da active
- 1993-06-29 DE DE69326977T patent/DE69326977T2/de not_active Expired - Lifetime
- 1993-06-29 ES ES93305086T patent/ES2141133T3/es not_active Expired - Lifetime
- 1993-06-29 WO PCT/US1993/006181 patent/WO1994000440A1/en active IP Right Grant
- 1993-06-29 AU AU46561/93A patent/AU4656193A/en not_active Abandoned
- 1993-08-17 TW TW082106583A patent/TW358808B/zh not_active IP Right Cessation
-
1994
- 1994-12-19 BG BG99274A patent/BG62963B1/bg unknown
- 1994-12-28 FI FI946133A patent/FI111363B/fi not_active IP Right Cessation
- 1994-12-28 NO NO945064A patent/NO305698B1/no not_active IP Right Cessation
-
1997
- 1997-04-30 BR BR1100375-8A patent/BR1100375A/pt active IP Right Grant
-
1998
- 1998-08-12 HK HK98109867A patent/HK1009268A1/xx not_active IP Right Cessation
-
1999
- 1999-11-11 GR GR990402842T patent/GR3031824T3/el unknown
-
2000
- 2000-09-07 LV LVP-00-118A patent/LV12568B/lv unknown
- 2000-11-02 CY CY0000052A patent/CY2200B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94046364A (ru) | Замещенные гетероциклы, способ их получения, фармокомпозиция, способ лечения | |
NZ311403A (en) | Imidazole compounds and pharmaceuticals | |
EE9800080A (et) | (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid | |
DK0675886T3 (da) | Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister | |
PT912176E (pt) | Utilizacao de amidas do acido piridil-alcanoico piridil-alcenoico e/ou piridil-alcinico para o tratamento de tumores ou para imunossupressao | |
EA200000298A1 (ru) | Агонисты простагландинов и их применение для лечения заболеваний костей | |
RU94042393A (ru) | Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих | |
RU94031102A (ru) | Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний | |
DE69618820T2 (de) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren | |
DE69616480T2 (de) | Piperidinderivate als neurokininantagonisten | |
DE69425267T2 (de) | 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten | |
ATE221885T1 (de) | Substituierte sulfonylphenylheterocyclen als cyclooxygenase-2 und 5- lipoxygenase inhibitoren | |
ATE337316T1 (de) | Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen | |
DK0807633T3 (da) | Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner | |
PT705100E (pt) | Guanidinas substituidas terapeuticas | |
NO20001483L (no) | Nye NPY-agonister | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
DE69838882D1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ATE139226T1 (de) | Aminosulfonylharnstoff-acat-inhibitoren | |
DE69429856D1 (de) | Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit | |
ATE263239T1 (de) | Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2) | |
NO991734L (no) | Pyrazolinoner for behandling av potensforstyrrelser | |
ATE187956T1 (de) | Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel | |
ATE224387T1 (de) | N-(pyridinylamino)isoindoline und verwandte verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner | ||
PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20130530 |
|
PD4A | Correction of name of patent owner |